Department of Minimally Invasive Intervention, Peking University Shenzhen Hospital, Shenzhen, Guangdong, 518036, China.
Health Management Center of Peking University Shenzhen Hospital, Shenzhen, Guangdong, 518036, China.
Int J Med Sci. 2019 Jan 29;16(3):424-442. doi: 10.7150/ijms.30154. eCollection 2019.
T-cell lymphomas are a heterogeneous group of cancers with different pathogenesis and poor prognosis. Histone deacetylases (HDACs) are epigenetic modifiers that modulate many key biological processes. In recent years, HDACs have been fully investigated for their roles and potential as drug targets in T-cell lymphomas. In this review, we have deciphered the modes of action of HDACs, HDAC inhibitors as single agents, and HDACs guided combination therapies in T-cell lymphomas. The overview of HDACs on the stage of T-cell lymphomas, and HDACs guided therapies both as single agents and combination regimens endow great opportunities for the cure of T-cell lymphomas.
T 细胞淋巴瘤是一组异质性癌症，具有不同的发病机制和不良预后。组蛋白去乙酰化酶 (HDACs) 是一种表观遗传修饰物，可调节许多关键的生物学过程。近年来，HDACs 的作用及其作为 T 细胞淋巴瘤药物靶点的潜力已被充分研究。在这篇综述中，我们阐明了 HDACs、HDAC 抑制剂作为单一药物以及 HDAC 指导的联合治疗在 T 细胞淋巴瘤中的作用机制。HDACs 在 T 细胞淋巴瘤阶段的概述以及 HDACs 指导的单一药物和联合治疗方案都为 T 细胞淋巴瘤的治愈提供了很好的机会。
